Company: IMNN
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001493152-25-022120
Chunk: 12

Company: Imunon, Inc.
Filing Date: 2025-11-13
Form: 10-Q
Item: Part I, Item 8
Chunk 12
---
28, 2025. On July 11, 2025, the Company’s
stockholders approved the issuance of the Warrants.

Note
8. Stock-Based Compensation

The
Company has long-term compensation plans that permit the granting of equity-based awards in the form of stock options, restricted stock,
restricted stock units, stock appreciation rights, other stock awards, and performance awards.

In
2018, stockholders approved the Imunon, Inc. 2018 Stock Incentive Plan (the “2018 Plan”). The 2018 Plan, as amended, permits
the granting of 131,334 shares of Imunon common stock as equity awards in the form of incentive stock options, nonqualified stock options,
restricted stock, restricted stock units, stock appreciation rights, other stock awards, performance awards, or in any combination of
the foregoing.

As
of September 30, 2025, there were a total of 264,667 shares of Imunon common stock reserved for issuance under the 2018 Plan, which were
comprised of 24,986 shares of Imunon common stock subject to equity awards previously granted under the 2018 Plan and 235,509 shares
of Imunon common stock available for future issuance under the 2018 Plan. At the 2025 Annual Stockholders Meeting of the Company held
on July 11, 2025, stockholders approved an amendment to the 2018 Plan, as previously amended, whereby the Company increased the number
of shares of common stock available by 133,333 to a total of 264,667 under the 2018 Plan, as amended.

Total
compensation cost related to stock options and restricted stock awards was approximately $0.1 million and $0.4 million of expense for
the nine months ended September 30, 2025 and 2024, respectively. Of these amounts, approximately $29,000 for the nine months ended September
30, 2025 and $0.2 million expense for the same period ended September 30, 2024 were charged to research and development expenses and
$0.1 million of expense for the nine months ended September 30, 2025 and $0.2 million of expense for the nine months ended September
30, 2024 were charged to general and administrative expenses.

    14

A
summary of stock option awards and restricted stock grants, inclusive of awards granted under the 2018